Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients. Objectives The primary outcome was major bleeding. Secondary out...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of thrombosis and haemostasis Ročník 18; číslo 2; s. 411 - 421
Hlavní autoři:	McBane, Robert D., Wysokinski, Waldemar E., Le‐Rademacher, Jennifer G., Zemla, Tyler, Ashrani, Aneel, Tafur, Alfonso, Perepu, Usha, Anderson, Daniel, Gundabolu, Krishna, Kuzma, Charles, Perez Botero, Juliana, Leon Ferre, Roberto A., Henkin, Stanislav, Lenz, Charles J., Houghton, Damon E., Vishnu, Prakash, Loprinzi, Charles L.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Limited 01.02.2020
Témata:	Anticoagulants Anticoagulants - adverse effects apixaban Bleeding Cancer Chemotherapy dalteparin Dalteparin - adverse effects Heparin Humans Malignancy Metastases Neoplasm Recurrence, Local Pyrazoles Pyridones Thromboembolism Treatment Outcome venous thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - drug therapy cancer bleeding apixaban venous thromboembolism dalteparin
ISSN:	1538-7933, 1538-7836, 1538-7836
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!